drugset / Trial / NCT03538951
Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Phase 2
Completed
83 enrolled
Vidac Pharma
Medistat Ltd., Israel · collabPharPoint Research, Inc. · collabTherapeutics, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days). This study has no placebo and the subjects enrolled in the study will know exactly what they are receiving. The objectives of the study are to evaluate the safety and benefit of these two strengths.
Timeline
- Start
- 2018-05-23
- Primary completion
- 2018-12-10
- Completion
- 2018-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VDA-1102 | Unknown | 10 % | Topical |
| Subject | VDA-1102 | Unknown | 20 % | Topical |